. The normal range for serum iron in this laboratory is 60-130 ,ug/lOO ml and for TIBC 300-350,ug/lOOml. Abbreviations:
MCHC, Mean corpuscular haemoglobin concentration ; TIBC, Total iron binding capacity.
Creatinine Case Sex Age Haemoglobin MCHC Serum iron TIBC Serum creatinine clearance no.
(g/100 ml) (%) (.ug/lOO ml) (pg/lOO ml) (mg/100 ml) (ml/min) Using the Merlin mobile whole-body radioactivity monitor (Boddy, 1967) , the countingrate due to natural body radioactivity was measured in eight patients (four males and four females) who fasted overnight and were given oral doses of 5 mg of ferric iron labelled with 0.1 yCi of 59Fe, made up with water to a total volume of 150 ml. After taking the dose the patients fasted for a further hour. Measurements of whole-body radioactivity were made at 4 h and at 21 days after administration. From these measurements the percentage absorption of iron was calculated as described previously (Will & Boddy, 1967) .
After a pre-treatment whole-body measurement, all ten patients were given an intravenous dose of 1.0 pCi of 59Fe. Whole body *'Fe radioactivity was measured on the day of administration, giving the counting-rate equivalent to 100% retention, and then sequentially up to 147 days after administration. Counting-rates were corrected as reported previously (Will & Boddy, 1967) and, where appropriate, allowance was made for 59Fe remaining from the absorption test. The exponential rate of loss from the body of 59Fe was calculated by the method of least-squares.
Blood samples were withdrawn 10-14 days after administration of the intravenous dose of 59Fe and the percentage incorporation of 59Fe into erythrocytes was estimated as described previously (Boddy et al., 1970) . Serum iron concentrations and total iron binding capacity were estimated by the methods of Ramsay (1957a, b) . The creatinine clearance was estimated using a standard autoanalyser technique (Technicon Instrument Company).
R E S U L T S
Measurement of oral iron absorption, incorporation of iron into erythrocytes and daily iron loss are summarized in Table 2 . Values obtained in four patients before insertion of the renal , 1971) of normal subjects and of non-dialysed and dialysed patients with chronic renal failure is given in Table 3 . The mean iron absorption of the present patients was intermediate between that of normal subjects and of both dialysed and non-dialysed patients with chronic renal failure. The results obtained in the transplanted patients were significantly lower than those in the normal subjects (P<0.05) and significantly higher than those in the dialysed patients (P < 0.05). The difference between transplanted patients and non-dialysed patients was not statistically significant (P >0.05).
Incorporation of 59Fe into erythrocytes in the transplanted patients was again intermediate between that in the normal subjects and that in the non-dialysed and dialysed patients, being significantly lower than in the normals (PxO.05) and higher than in the dialysed patients (P< 0.05).
The exponential rate of loss of 59Fe from the body was similar to that reported in normal subjects and in non-dialysed patients with chronic renal failure and significantly lower than that observed in dialysed patients (P< 0.05).
In the four patients whose iron metabolism had been studied before nephrectomy and transplantation, while the patients were receiving regular dialysis treatment, a paired analysis showed that incorporation of 59Fe into erythrocytes was significantly greater (P< 0.05) and that losses of iron were significantly decreased (P< 0.05) after insertion of the homografts. Absorption values before and after transplantation were available for only two patients. 
D I S C U S S I O N
Renal function in all patients in the present study was reasonable so that dialysis therapy was not required. The creatinine clearance rates ranged from 30 to 106 (mean 65) ml/min.
The association of anaemia with chronic renal failure is well recognized and the severity is usually quantitatively related to the severity of the renal failure. Erslev (1970) and Desforges (1970) and others suggest that the anaemia of chronic renal failure arises primarily from defective erythropoiesis due to decreased or absent production of erythropoietin by the kidney.
In previous studies (Boddy et al., 1970; Lawson et al., 1971) we found that thirteen of nineteen non-dialysed patients with chronic renal failure were severely anaemic, with haemoglobin concentrations below 8 g/lOO ml; all seventeen patients with chronic renal failure receiving regular dialysis treatment were severely anaemic. An interesting finding in the present study is that only three of the ten patients with functioning renal homografts were anaemic and in no instance was this severe, the haemoglobin concentrations being 10.2, 11.7 and 11.8 g/100 ml respectively. Precise definition of the body iron status of the patients was not possible because repeated bone marrow aspirations were not considered ethically justifiable. Uncertainties in relating iron status to serum iron content and to total serum iron binding capacity have previously been acknowledged (Boddy et al., 1970; Lawson et al., 1971) but it is of interest, nevertheless, that only one patient (case 6) had a serum iron content below the normal range for the laboratory reporting these values. This patient had a normal haemoglobin value and a high 59Fe erythrocyte incorporation value and could be considered at most to be marginally iron deficient. She had a source of blood loss after the return of menstruation.
Comparison of the present findings with those of our earlier studies (Boddy et al., 1970; Lawson et al., 1971) , showed that the mean values for oral absorption and 59Fe incorporation into erythrocytes were apparently related to the degree of renal function. In decreasing order were normal subjects, patients with renal homografts, non-dialysed patients, and dialysed patients with chronic renal failure. It should be noted, however, that the differences between the patients with renal homografts and the non-dialysed patients were not statistically significant (P>0.05). Rates of whole body "Fe loss were similar in normal subjects, renal homograft patients and patients with chronic renal failure not on dialysis. As all of the patients with renal homografts had been receiving long-term high-dosage steroid therapy, the demonstration of normal rates of loss of "Fe from the body was of considerable interest. The patients with chronic renal failure receiving regular dialysis therapy showed a highly significant ( P < 0.01) increase in the rate of whole body 59Fe loss. Four patients receiving regular dialysis treatment were initially studied before nephrectomy and were re-examined in the present study after successful insertion of a renal homograft (Table 1 , cases 2, 3, 7 and 9). While receiving dialysis therapy and before nephrectomy, these patients were all severely anaemic. After nephrectomy and the insertion of the renal homografts, all four showed considerable increases in haemoglobin concentrations, two actually attaining values within the normal range. In these four patients, highly significant increases in serum iron concentration and in serum transferrin saturation values and also increased incorporation of 59Fe into erythrocytes occurred after insertion of renal homografts.
Successful insertion of a renal homograft is followed by marked improvement in renal function as shown by the creatinine clearance test. The results reported above indicate that bone marrow function may also improve, resulting in increased erythropoiesis as shown by the return towards normal of the mean values for haemoglobin, percentage 59Fe incorporation into erythrocytes and percentage oral iron absorption.
